Topic resource collection
Approved comparison material connected to this topic.
83 resourcesRead both sides
BPC-157 VEGF upregulation, fibroblast migration, angiogenesis at injury site 250–500 mcg SC twice daily 4–6 weeks (collagen density) Moderate (indirectly through vascularization) Best for acute injuries and microtear repair. Addr…
BPC-157 (pentadecapeptide) Angiogenesis and epithelial proliferation VEGF receptor-2 activation, NO synthase stabilization Mucosal healing models, barrier reconstitution studies 10 mcg/kg intraperitoneally Histological damage sco…
KPV NF-κB inhibition in mast cells Anti-inflammatory Preclinical + case reports Topical Strongest evidence for erythema reduction; requires permeation enhancer BPC-157 Vascular stabilization, endothelial repair Angiogenesis modul…
Before selecting peptides for a research protocol, understanding their distinct mechanisms, dosing requirements, and evidence base is essential. BPC-157 Angiogenesis, mitochondrial stabilisation, oxidative stress reduction 10 mcg…
Before writing this table, here's what it shows: the only two peptides with documented circadian-relevant mechanisms (Epitalon and DSIP) compared against commonly marketed alternatives that lack circadian specificity. The 'Profes…
BPC-157 eNOS stabilization, VEGF upregulation, inflammatory cytokine suppression Acute (0–72 hours) 10 μg/kg Intraperitoneal BBB permeability, lesion volume, motor recovery Best for focal injuries with prominent vascular disrupti…
BPC-157 VEGF upregulation, angiogenesis, nitric oxide signaling 34% increase in nerve conduction velocity in diabetic rat models (12 weeks) Subcutaneous injection Strongest vascular repair evidence; most studied in peripheral ner…
BPC-157 VEGFR2 upregulation → angiogenesis, mucosal blood flow restoration Ethanol-induced, ischemia-reperfusion injury 10–50 mcg/kg IP or oral daily for 7–14 days Minimal effect in NSAID models where vascular injury is secondary…
GLP-1 Agonists (Semaglutide, Tirzepatide) Incretin receptor activation → insulin secretion, gastric emptying delay Hyperinsulinemia, androgen excess Strong clinical translation. Phase 3 data in PCOS populations Best for insulin-a…
MOTS-c Mitochondrial biogenesis upregulation via PGC-1alpha activation Complex I function, ROS reduction Intranasal, intraperitoneal 5–15 mg/kg IP 3×/week Reduced ROS, improved mitochondrial respiration in aged brain tissue (USC …
Semax BDNF upregulation via TrkB activation Synaptic plasticity, dendritic spine formation 10–100 μM (in vitro), 50–500 μg/kg (in vivo) Stable in PBS for 7 days at 4°C; degrades rapidly above pH 8.0 Best choice for studying synap…
BPC-157 Angiogenesis, mucosal protection VEGFR2, FAK-paxillin signaling 14–21 days for 60–70% lesion reduction 40+ preclinical studies in gastric injury models Strongest evidence for direct tissue repair; gold standard for gastri…
BPC-157 VEGF upregulation, collagen synthesis enhancement, inflammatory cytokine suppression 10 mcg/kg daily (subcutaneous) in animal models 28 days at 2–8°C 4–12 weeks Most studied for tendon-bone healing; angiogenic effects tra…
BPC-157 250–500mcg Daily (subcutaneous or IM) VEGF upregulation, angiogenesis, fibroblast proliferation Moderate. Rat tendon models show 70% strength increase at 14 days Small injection volume, daily commitment, requires bacterio…
BPC-157 Epithelial repair, angiogenesis VEGF upregulation, NOS stabilisation Rodent models: 60% faster healing; human case reports positive 250–500 mcg SC daily Most relevant for barrier dysfunction SIBO LL-37 Antimicrobial membr…
This table compares the primary peptides used in testosterone-related research based on mechanism, half-life, dosing frequency, and documented effects on gonadotropin pathways. CJC-1295 (with DAC) GHRH analogue. Stimulates sustai…
Before diving into protocol specifics, this table summarizes the three leading peptides studied for post-viral cognitive impairment. Their mechanisms, administration routes, and what research shows about their efficacy. Semax ACT…
BPC-157 VEGF modulation, nitric oxide pathway regulation Days 0–14 post-injury Reduces collagen III deposition by 25–40% vs controls; accelerates collagen I transition Promotes controlled angiogenesis; reduces vascular permeabili…
BPC-157 Growth hormone receptor activation in fibroblasts; upregulates FAK-paxillin pathway for cell migration and ECM remodelling Proliferative phase (days 7–21) 250–500mcg daily subcutaneous Human clinical trial data absent; do…
BPC-157 GABAergic modulation in basolateral amygdala Intraperitoneal 10 μg/kg daily ~4 hours GABA_A receptor density, freezing behavior in contextual fear conditioning Strongest signal in fear extinction protocols; requires IP ad…